Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1346.05% is 134% below its 5-year average of -575.09%, around the middle of its 5-year range (-2376.17%–-189.85%).
68.46% below its 12-month average of -799.05%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1182.72%.
EBITDA MARGIN
-1346.05%
EBITDA MARGIN AVG TTM
-799.05%
EBITDA MARGIN AVG 3Y
-569.40%
EBITDA MARGIN AVG 5Y
-575.09%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-68.46%
CURRENT VS 3Y AVG
-136.40%
CURRENT VS 5Y AVG
-134.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CytoMed Therapeutics Limited
Market Cap
$11.95M
EBITDA Margin
-1346.05%
TTM Avg
-799.05%
3Y Avg
-569.40%
5Y Avg
-575.09%
Market Cap
$12.46M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$11.41M
EBITDA Margin
-19.85%
TTM Avg
-31.46%
3Y Avg
-46.77%
5Y Avg
-56.23%
Market Cap
$12.63M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
Market Cap
$11.01M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
Market Cap
$10.74M
EBITDA Margin
-284.92%
TTM Avg
-261.31%
3Y Avg
-2315.78%
5Y Avg
-2461.07%
Market Cap
$13.34M
EBITDA Margin
-16245.70%
TTM Avg
-13416.38%
3Y Avg
-13330.05%
5Y Avg
-20098.17%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $11.95M | -1346.05% | -799.05% | -569.40% | -575.09% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -34.02% | -37.67% | -64.98% | -56.41% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -19.85% | -31.46% | -46.77% | -56.23% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.74M | -284.92% | -261.31% | -2315.78% | -2461.07% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.34M | -16245.70% | -13416.38% | -13330.05% | -20098.17% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -855.47% | -475.86% | -335.10% | -307.83% |
Gross Margin
N/A
EBITDA Margin
-1346.0%
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1182.72% |
| 2025-12-31 | -1324.64% |
| 2025-09-30 | -272.59% |
| 2025-06-30 | -416.24% |
| 2025-03-31 | -416.24% |
| 2024-12-31 | -2234.93% |
| 2024-09-30 | -307.94% |
| 2024-06-30 | -323.41% |
| 2024-03-31 | -398.82% |
| 2023-12-31 | -345.73% |
| 2023-09-30 | -312.19% |
| 2023-06-30 | -962.89% |
| 2023-03-31 | -642.62% |
| 2022-12-31 | -913.98% |
| 2022-09-30 | -189.85% |
| 2022-06-30 | -690.94% |
| 2022-03-31 | -591.20% |
| 2021-12-31 | -2376.17% |
| 2021-09-30 | -484.45% |
| 2021-03-31 | -1444.39% |
| 2020-12-31 | -933.69% |
| 2020-09-30 | -890.86% |
